OCGN250117P3000
- 1.75
- 0.000.00%
Ocugen Newsroom
Ocugen Inc. Stock Falls Tuesday, Underperforms Market
Ocugen Secures Data and Safety Monitoring Board Approval to Advance OCU410 Trial for Geographic Atrophy
Express News | Ocugen Inc - Dsmb Approves Continuation of Ocu410 Armada Phase 1/2 Study
Express News | Ocugen Inc: Ocu410 Has a Very Favorable Safety and Tolerability Profile
Express News | Data and Safety Monitoring Board Reviews Interim Safety Data of Phase 2 Subjects of Ocu410 Armada Clinical Trial for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
Data and Safety Monitoring Board Reviews Interim Safety Data of Phase 2 Subjects of OCU410 ArMaDa Clinical Trial for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
Ocugen CEO to Present at Oppenheimer Movers in Rare Disease Summit
Ocugen CEO to Present at NobleCon20 – Noble Capital Markets' 20th Annual Emerging Growth Equity Conference
Ocugen's Eye Disease Treatment Receives Orphan Drug Designation in Europe for Retinopathies
Express News | Ocugen Inc - to Pursue Accelerated Marketing Authorization Application for Ocu410St
Express News | Ocugen Announces European Medicines Agency Grants Orphan Medicinal Product Designation for Modifier Gene Therapy Candidate Ocu410St for Treatment of Abca4-Associated Retinopathies Including Stargardt Disease
Ocugen Announces European Medicines Agency Grants Orphan Medicinal Product Designation for Modifier Gene Therapy Candidate OCU410ST for Treatment of ABCA4-Associated Retinopathies Including Stargardt Disease
Ocugen, Inc. Reports Positive Preliminary Data From OCU410 Clinical Trial for Geographic Atrophy in Dry Age-Related Macular Degeneration
Ocugen Announces Preliminary Data For OCU410l; Findings Included No Drug-related Serious Adverse Events, Reduced Lesion Growth, Preservation Of Retinal Tissue, Positive Effect On The Functional Visual Measure Of Low Luminance Visual Acuity
Express News | Ocugen Announces Compelling Preliminary Data for Ocu410—a Single Dose Novel Modifier Gene Therapy to Treat Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
Ocugen Announces Compelling Preliminary Data for OCU410—a Single Dose Novel Modifier Gene Therapy to Treat Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
Ocugen Price Target Maintained With a $6.00/Share by Chardan Capital
Ocugen Is Maintained at Buy by Chardan Capital
The "Diet Duo" leads a sharp decline in pharmaceutical stocks, as Trump's new health secretary opposes vaccines and weight loss drugs.
Kennedy, known as the "anti-vaccine pioneer," strongly opposes GLP-1 drugs, believing they are the wrong approach to addressing the obesity crisis. On Friday, the stock prices of the "weight loss giants" eli lilly and co and novo-nordisk a/s fell by 4.93% and 3.4%, respectively, and other companies dedicated to developing weight loss drugs also suffered heavy losses.
Ocugen Appoints Ramesh Ramachandran as Financial Officer